
Early-onset drusen maculopathy (EODM), is part of the age-related macular degeneration (AMD) phenotype that occurs in individuals under 55 years of age.

Early-onset drusen maculopathy (EODM), is part of the age-related macular degeneration (AMD) phenotype that occurs in individuals under 55 years of age.

EODM may be an ideal candidate for development of complement gene therapy due to the high-impact genetic variants.

EODM may be an ideal candidate for development of complement gene therapy due to the high-impact genetic variants

SriniVas R. Sadda, MD, sat down with David Hutton of Ophthalmology Times to discuss his presentation about precursor lesions for development of atrophy and AMD from the Angiogenesis Exudation and Degeneration 2024 event.

Multimodal technology bridges the gap between advanced age-related macular degeneration (AMD) biomarkers and clinical features.

Researchers aimed to develop a translational map to understand how advanced imaging biomarkers manifest in typical diagnostic imaging


This presentation will outline the safety and bioactivity of KSI-501ABC in patients with diabetic macular edema (DME).

The afternoon sessions begin after lunch and continue well into the evening at the Angiogenesis, Exudation, and Degeneration 2024 meeting

The one-day event will be held online Saturday, February 3, 2024, and is sponsored by the Bascom Palmer Eye Institute, University of Miami Health System

The afternoon sessions promise to be engaging and informative in this virtual conference.

John T. Thompson, MD, FASRS, shares pearls for navigating the diverse landscape of career paths in ophthalmology as the Distinguished Guest Speaker at the 24th Annual Retina Fellows Forum.

This meeting, scheduled for Saturday, February 3, 2024, is a 1-day virtual event sponsored by the Bascom Palmer Eye Institute, Miami, University of Miami Health System.

Leanne Clevenger, MD, described a case that highlights varying approaches and protocols for addressing a complex case of retinal detachment repair in a patient with trauma to the globe.

David Hutton of Ophthalmology Times talks with Adrienne Scott, MD, FASRS, about her part in a panel discussion detailing emerging therapies for AMD.

David Hutton of Ophthalmology Times talks with Sunir Garg, MD about his surgical video panel at this year's Retina Fellows Forum.

Allen Ho, MD, FACS, FASRS, will make a presentation at the meeting, to be held virtually on February 3.

Bonnie An Henderson, MD, previews the EnVision Summit 2024, scheduled for February 16 to 19 in Puerto Rico, highlighting its family friendly atmosphere, diverse specialty coverage, and new sessions on leadership and health equity.

Roger A. Goldberg, MD, MBA, presents a post hoc analysis of the Phase 2/3 PHOTON trial, offering insights into the potential benefits of 8 mg aflibercept in managing fluid reaccumulation, particularly in cases of diabetic macular edema.

Principle findings showed that aflibercept 8 mg demonstrated similar improvements in BCVA and CST when compared to the 2 mg dose of aflibercept.

David A. Eichenbaum, MD, discusses the promising aspects of gene augmentation for treating common retinal diseases, addresses concerns about perpetual protein production, and considers the potential positive impact on patients by reducing treatment burdens.

David Eichenbaum, MD, discussed the status of the technology at the Retina 2024 meeting in Maui.

Glenn J. Jaffe, MD, discusses the multifactorial complexities of treating patients with geographic atrophy.

The Annual Gala will be held on February 8 from 6 to 9 pm Pacific Standard Time.

David Hutton of Ophthalmology Times talks with Eric Donnenfeld, MD about his presentation "Small Aperture IOL for Irregular Corneas" at this year's Hawaiian Eye and Retina 2024 Meeting.

Patient selection is important.

David Hutton of Ophthalmology Times talks with William Trattler, MD, about his presentation "Toric IOL pearls for Correcting Lower Levels of Astigmatism" at this year's Hawaiian Eye and Retina 2024 Meeting.

Varun Chaudhary, MD, FRCSC, addressed the big questions in treating patients with retinal vascular diseases at the Retina 2024 meeting in Maui.

GreenMan app provides patients an opportunity to test drive various IOL options before cataract surgery via virtual and augmented reality.

Vascular compromise is the most ominous early adverse event that can occur when a filler is unintentionally injected into a blood vessel.